<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789761</url>
  </required_header>
  <id_info>
    <org_study_id>MCStudy</org_study_id>
    <nct_id>NCT02789761</nct_id>
  </id_info>
  <brief_title>The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males</brief_title>
  <official_title>The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, placebo-controlled, parallel human dietary intervention trial conducted in 33
      healthy males to investigate the vascular and cognitive effects of bi-daily consumption of
      high-flavanol (epicatechin-rich) milk chocolate over a 2-week intervention period. Subjects
      visited the Hugh Sinclair Unit of Human Nutrition on 3 separate occasions; at the beginning,
      end and post-intervention.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated Dilation (FMD)</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>Ultrasound-based assessment of brachial artery reactivity following induced reactive hyperemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (BP)</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>Acute assessment of systolic and diastolic BP (3 repeats)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Function</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>Assessed by cognitive test battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial progenitor cells and Microparticles</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>Flow cytometric analysis using whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma flavanol metabolite analysis</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>HPLC-MS assessment of metabolite profile and content of plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Nitrite &amp; Nitrate analysis</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>HPLC-based system with inbuilt colorimetric Griess reaction assay for the assessment of Nitrite &amp; Nitrate in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum analysis of cardivascular-related blood marker(s) concentration</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>ILAB assessment of serum content of glucose, Triglycerides, total cholesterol, HDL-cholesterol, C-reactive protein and Non-esterified fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum analysis of insulin</measure>
    <time_frame>Change from baseline at 14 days</time_frame>
    <description>ELIZA kits for determination of insulin concentration in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High-flavanol milk chocolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-flavanol milk chocolate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately &lt;1 mg of (-)-epicatechin for 2-weeks (14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-flavanol milk choocolate</intervention_name>
    <arm_group_label>High-flavanol milk chocolate</arm_group_label>
    <other_name>Epicatechin-rich milk chocolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-flavanol milk chocolate</intervention_name>
    <arm_group_label>Low-flavanol milk chocolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Body Mass Index 18.5-27.5 kg/m2

          -  Normal Blood pressure (&lt; 150/90)

          -  Non-smoker

          -  Regular exercise routine

          -  Signed consent form

        Exclusion Criteria:

          -  Haemoglobin (anaemia marker) &lt; 125 g/l

          -  Gamma GT (liver enzymes) &gt; 80 IU/l

          -  Total Cholesterol &gt; 6.5 mmol/l

          -  Suffered a myocardial infarction or stroke in the last 12 months

          -  Suffers from any cardiovascular or metabolic disorders

          -  Suffers from any blood-clotting disorder, and/or takes supporting medication

          -  Any dietary restrictions or on a weight reducing diet

          -  On any lipid-modifying or blood pressure lowering medication

          -  Consuming any specific vitamin/ herbal supplements or fish oils
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy P Spencer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerisity of Reading</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Jeremy Paul Edward Spencer</investigator_full_name>
    <investigator_title>Professor of Biochemistry</investigator_title>
  </responsible_party>
  <keyword>Flow-mediated dilatation (FMD)</keyword>
  <keyword>Vascular function</keyword>
  <keyword>cognitive function</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

